This article is more than 5 years old. Information may no longer be current.

Accommodating IOL shows better visual results over previous version in FDA trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — The Crystalens HD showed improved visual results over the Crystalens AT-45 in FDA clinical trial results, according to a speaker here.

"The Crystalens HD showed increased depth of field over the Crystalens AT-45, and a greater percentage of HD eyes achieved J1 and J2 uncorrected and with distance vision," John Hovanesian, MD, said here at Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Dr. Hovanesian also said the HD IOL showed no loss of contrast sensitivity compared with the AT-45. The Crystalens HD IOL and Crystalens AT-45 are both manufactured by Bausch & Lomb.